Carolyn M Wilhelm1, Kristen V Truxal2, Kim L McBride3, John P Kovalchin4, Kevin M Flanigan5. 1. Divisions of Cardiology, Nationwide Children's Hospital, Columbus, OH, United States. Electronic address: Carolyn.Wilhelm@uhhospitals.org. 2. Divisions of Genetic and Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, United States; Departments of Pediatrics, Nationwide Children's Hospital, Columbus, OH, United States. 3. Divisions of Genetic and Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, United States; Center for Cardiovascular Research, Nationwide Children's Hospital, Columbus, OH, United States; Departments of Pediatrics, Nationwide Children's Hospital, Columbus, OH, United States. 4. Divisions of Cardiology, Nationwide Children's Hospital, Columbus, OH, United States; Departments of Pediatrics, Nationwide Children's Hospital, Columbus, OH, United States. 5. Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, United States; Departments of Pediatrics, Nationwide Children's Hospital, Columbus, OH, United States; Departments of Neurology, The Ohio State University, Columbus, OH, United States.
Abstract
BACKGROUND: Mucopolysaccharidosis (MPS) type III, Sanfilippo Syndrome, is an autosomal recessive lysosomal storage disorder. MPS I and II patients often develop cardiac involvement leading to early mortality, however there are limited data in MPS III. The objective of this study is to describe cardiac abnormalities in a large group of MPS III patients followed in a longitudinal natural history study designed to determine outcome measures for gene transfer trials. METHODS: A single center study of MPS III patients who were enrolled in the Nationwide Children's Hospital natural history study in 2014. Two cardiologists reviewed all patient echocardiograms for anatomic, valvular, and functional abnormalities. Valve abnormalities were defined as abnormal morphology, trivial mitral regurgitation (MR) with abnormal morphology or at least mild MR, and any aortic regurgitation (AR). Abnormal left ventricular (LV) function was defined as ejection fraction < 50%. Group comparisons were assessed using two-sample t-tests or Wilcoxon rank sum tests for continuous variables and chi-square or Fisher's exact tests for categorical variables. RESULTS: Twenty-five patients, 15 Type A and 10 Type B MPS III, underwent 45 echocardiograms. Fifteen patients (60%) demonstrated an abnormal echocardiographic finding with age at first abnormal echocardiogram within the study being 6.8 ± 2.8 years. Left-sided valve abnormalities were common over time: 7 mitral valve thickening, 2 mitral valve prolapse, 16 MR (8 mild, 8 trivial), 3 aortic valve thickening, and 9 AR (7 mild, 2 trivial). Two patients had asymmetric LV septal hypertrophy. No valvular stenosis or ventricular function abnormalities were noted. Incidental findings included: mild aortic root dilation (2), bicommissural aortic valve (1), and mild tricuspid regurgitation (3). CONCLUSIONS: Individuals with Sanfilippo A and B demonstrate a natural history of cardiac involvement with valvular abnormalities most common. In short-term follow up, patients demonstrated only mild progression of abnormalities, none requiring intervention. Valvular disease prevalence is similar to MPS I and II, but appears less severe. These findings raise no specific concerns for gene transfer trials in patients in this age range.
BACKGROUND:Mucopolysaccharidosis (MPS) type III, Sanfilippo Syndrome, is an autosomal recessive lysosomal storage disorder. MPS I and II patients often develop cardiac involvement leading to early mortality, however there are limited data in MPS III. The objective of this study is to describe cardiac abnormalities in a large group of MPS IIIpatients followed in a longitudinal natural history study designed to determine outcome measures for gene transfer trials. METHODS: A single center study of MPS IIIpatients who were enrolled in the Nationwide Children's Hospital natural history study in 2014. Two cardiologists reviewed all patient echocardiograms for anatomic, valvular, and functional abnormalities. Valve abnormalities were defined as abnormal morphology, trivial mitral regurgitation (MR) with abnormal morphology or at least mild MR, and any aortic regurgitation (AR). Abnormal left ventricular (LV) function was defined as ejection fraction < 50%. Group comparisons were assessed using two-sample t-tests or Wilcoxon rank sum tests for continuous variables and chi-square or Fisher's exact tests for categorical variables. RESULTS: Twenty-five patients, 15 Type A and 10 Type B MPS III, underwent 45 echocardiograms. Fifteen patients (60%) demonstrated an abnormal echocardiographic finding with age at first abnormal echocardiogram within the study being 6.8 ± 2.8 years. Left-sided valve abnormalities were common over time: 7 mitral valve thickening, 2 mitral valve prolapse, 16 MR (8 mild, 8 trivial), 3 aortic valve thickening, and 9 AR (7 mild, 2 trivial). Two patients had asymmetric LV septal hypertrophy. No valvular stenosis or ventricular function abnormalities were noted. Incidental findings included: mild aortic root dilation (2), bicommissural aortic valve (1), and mild tricuspid regurgitation (3). CONCLUSIONS: Individuals with Sanfilippo A and B demonstrate a natural history of cardiac involvement with valvular abnormalities most common. In short-term follow up, patients demonstrated only mild progression of abnormalities, none requiring intervention. Valvular disease prevalence is similar to MPS I and II, but appears less severe. These findings raise no specific concerns for gene transfer trials in patients in this age range.
Authors: Raymond Y Wang; Kelly K Covault; Eileen M Halcrow; Audrey J Gardner; Xiaoling Cao; Robert L Newcomb; Richard D Dauben; Anthony C Chang Journal: Mol Genet Metab Date: 2011-09-10 Impact factor: 4.797
Authors: Leo Lopez; Steven D Colan; Peter C Frommelt; Gregory J Ensing; Kathleen Kendall; Adel K Younoszai; Wyman W Lai; Tal Geva Journal: J Am Soc Echocardiogr Date: 2010-05 Impact factor: 5.251
Authors: William A Zoghbi; David Adams; Robert O Bonow; Maurice Enriquez-Sarano; Elyse Foster; Paul A Grayburn; Rebecca T Hahn; Yuchi Han; Judy Hung; Roberto M Lang; Stephen H Little; Dipan J Shah; Stanton Shernan; Paaladinesh Thavendiranathan; James D Thomas; Neil J Weissman Journal: J Am Soc Echocardiogr Date: 2017-03-14 Impact factor: 5.251
Authors: Francesco Borgia; Enrica Pezzullo; Vincenzo Schiano Lomoriello; Regina Sorrentino; Francesco Lo Iudice; Sara Cocozza; Roberto Della Casa; Giancarlo Parenti; Pietro Strisciuglio; Bruno Trimarco; Maurizio Galderisi Journal: Echocardiography Date: 2017-01-10 Impact factor: 1.724
Authors: K V Truxal; H Fu; D M McCarty; K A McNally; K L Kunkler; N A Zumberge; L Martin; S C Aylward; L N Alfano; K M Berry; L P Lowes; M Corridore; C McKee; K L McBride; K M Flanigan Journal: Mol Genet Metab Date: 2016-08-18 Impact factor: 4.797
Authors: Elizabeth A Braunlin; Paul R Harmatz; Maurizio Scarpa; Beatriz Furlanetto; Christoph Kampmann; James P Loehr; Katherine P Ponder; William C Roberts; Howard M Rosenfeld; Roberto Giugliani Journal: J Inherit Metab Dis Date: 2011-07-09 Impact factor: 4.982
Authors: Maria Paola Belfiore; Francesca Iacobellis; Emma Acampora; Martina Caiazza; Marta Rubino; Emanuele Monda; Maria Rosaria Magaldi; Antonietta Tarallo; Marcella Sasso; Valeria De Pasquale; Roberto Grassi; Salvatore Cappabianca; Paolo Calabrò; Simona Fecarotta; Salvatore Esposito; Giovanni Esposito; Antonio Pisani; Luigi Michele Pavone; Giancarlo Parenti; Giuseppe Limongelli Journal: PLoS One Date: 2020-05-19 Impact factor: 3.240
Authors: Stephanie C M Nijmeijer; L Ingeborg van den Born; Anneke J A Kievit; Karolina M Stepien; Janneke Langendonk; Jan Pieter Marchal; Susanne Roosing; Frits A Wijburg; Margreet A E M Wagenmakers Journal: Orphanet J Rare Dis Date: 2019-11-12 Impact factor: 4.123
Authors: Jordan E Morningstar; Annah Nieman; Christina Wang; Tyler Beck; Andrew Harvey; Russell A Norris Journal: J Am Heart Assoc Date: 2021-06-22 Impact factor: 5.501